This study is for people with Triple-negative Breast Cancer (TNBC) who did not completely respond to prior treatments. TNBC is a type of breast cancer that doesn't have three specific receptors (proteins) that other breast cancers have. In this study, researchers are testing two drugs, Dato-DXd and Durvalumab, alone or together, against the usual treatment chosen by doctors, called Investigator's Choice Therapy (ICT). ICT includes drugs like capecitabine and pembrolizumab. The goal is to see which option works best at preventing cancer from coming back.

• The study involves multiple visits to different locations, as it's an international study.
• Participants must be 18 years or older and have had certain previous treatments.
• There are specific health conditions that might prevent participation, like other severe diseases or infections.

If you think you might qualify and are interested in participating, discuss it with your doctor. They can help you understand if this study is a good option for you.